openPR Logo
Press release

Respiratory Syncytial Virus (RSV) Therapeutics Market 2024-2033: Future Outlook, Global Trends, Industry Share And Top Key Players

04-24-2024 07:39 AM CET | Health & Medicine

Press release from: The Business Research Company

Respiratory Syncytial Virus (RSV) Therapeutics Market

Respiratory Syncytial Virus (RSV) Therapeutics Market

The respiratory syncytial virus (rsv) therapeutics market size has grown exponentially in recent years. It will grow from $1.27 billion in 2023 to $1.59 billion in 2024 at a compound annual growth rate (CAGR) of 25.2%. The growth in the historic period can be attributed to disease awareness, advancements in virology, pediatric vulnerability, epidemic outbreaks, vaccine development.

The respiratory syncytial virus (rsv) therapeutics market size is expected to see exponential growth in the next few years. It will grow to $3.69 billion in 2028 at a compound annual growth rate (CAGR) of 23.4%. The growth in the forecast period can be attributed to biologic therapies innovation, emerging antivirals, focus on elderly population, maternal immunization strategies, global research collaborations. Major trends in the forecast period include monoclonal antibodies advancements, nasal vaccines and delivery systems, combination therapies, novel drug delivery systems, home-based treatment options.

Market Overview -
Respiratory syncytial virus (RSV) therapeutics refers to the treatments and medications employed to manage and treat infections caused by the respiratory syncytial virus. Respiratory syncytial virus is a common respiratory virus that can cause mild to severe respiratory illness, particularly in infants, young children, older adults, and individuals with weakened immune systems.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12601&type=smp

The Rise In The Prevalence Of Rsv Infection
The rise in the prevalence of RSV infection is driving the growth of the respiratory syncytial virus (RSV) therapeutics market going forward. RSV is a prevalent respiratory illness that can result in mild to severe respiratory infections, especially in newborns, young children, elderly adults, and people with compromised immune systems. Increasing RSV infections prompt the development of innovative treatments to address the rising need and mitigate the severity of RSV-related complications. For instance, in September 2022, according to the article published by The Lancet, a UK-based book and periodic data publishing organization, around 11,255 new cases of RSV were recorded in the 2021 summer, which is 9.50% more compared to 10,280 cases in winter 2020-21. Therefore, the rise in the prevalence of RSV infection propels the growth of the respiratory syncytial virus (RSV) therapeutics market.

Competitive Landscape -
Major companies operating in the respiratory syncytial virus (rsv) therapeutics market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc., Gilead Sciences Inc., Moderna Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Dr. Reddy's Laboratories Ltd., Bio-Rad Laboratories Inc., Novavax AB, Vir Biotechnology Inc., Lupin Limited, Kyorin Pharmaceutical Co. Ltd., Bavarian Nordic A/S, SciClone Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Hetero Healthcare Ltd, Inovio Pharmaceuticals Inc., Ascletis Pharma Inc., NanoBio Corporation, Vaxart Inc., Ark Biosciences Private Limited, Pulmocide Ltd

Pfizer's Abrysvo Approval Marks A Significant Advancement In Respiratory Syncytial Virus (RSV) Therapeutics
Developing new drugs and vaccines with better efficacy is a key trend gaining popularity in the respiratory syncytial virus (RSV) therapeutics market. Major companies operating in the respiratory syncytial virus (RSV) therapeutics market are focused on developing new drugs and vaccines to sustain their position in the market. For instance, in May 2023, Pfizer Inc., a US-based pharmaceutical manufacturing company, received approval from the Food and Drug Administration, a US-based federal agency responsible for protecting and promoting public health, for ABRYSVO. The bivalent RSV prefusion F (RSVpreF) vaccine ABRYSVO (Respiratory Syncytial Virus Vaccine) is administered to prevent lower respiratory tract sickness caused by RSV in people 60 and older. ABRYSVO is an unadjuvanted vaccine made up of a pair of preF proteins tailored to maximize immunity to RSV A and B varieties, and it has been clinically proven to be safe and productive.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/respiratory-syncytial-virus-rsv-therapeutics-global-market-report

Key Segments -
The respiratory syncytial virus (rsv) therapeutics market covered in this report is segmented -
1) By Drug: Palivizumab, Ribavirin, Other Drugs
2) By Treatment: Immune Prophylaxis, Supportive Care, Antiviral Medications
3) By Dosage Form: Oral, Injectable, Other Dosage Forms
4) By Patient Type: Pediatrics, Adults
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Respiratory Syncytial Virus (RSV) Therapeutics Market 2024-2033: Future Outlook, Global Trends, Industry Share And Top Key Players here

News-ID: 3474188 • Views:

More Releases from The Business Research Company

2024 Global Type 2 Diabetes Market Size, Share, Trends And Growth Analysis Report | F. Hoffmann-La Roche AG, Merck and Co. Inc., Novartis AG, AstraZeneca PLC, Abbott Laboratories
2024 Global Type 2 Diabetes Market Size, Share, Trends And Growth Analysis Repor …
"The type 2 diabetes market size has grown strongly in recent years. It will grow from $44.56 billion in 2023 to $48.14 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to lifestyle and dietary changes, aging population, pharmaceutical developments, public health initiatives. The type 2 diabetes market size is expected to see strong growth in the
Global Esophageal Dysphagia Market 2024 : SWOT Analysis Of Key Driving Factors For Growing CAGR Value | Nestle Health Science S.A., Novartis AG, Fresenius Kabi AG, Abbott Laboratories, Danone S.A
Global Esophageal Dysphagia Market 2024 : SWOT Analysis Of Key Driving Factors F …
"The esophageal dysphagia market size has grown strongly in recent years. It will grow from $1.96 billion in 2023 to $2.08 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to aging population, gastroesophageal reflux disease (gerd), advances in endoscopy, esophageal motility testing. The esophageal dysphagia market size is expected to see strong growth in the next
Osteoarthritis Market 2024 Analysis By Size, Share, Growth, Trends Up To 2033 | Pfizer Inc., Johnson & Johnson, Merck Sharp & Dohme Corp.
Osteoarthritis Market 2024 Analysis By Size, Share, Growth, Trends Up To 2033 | …
"The osteoarthritis market size has grown rapidly in recent years. It will grow from $6.24 billion in 2023 to $6.87 billion in 2024 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to aging population, obesity epidemic, advances in imaging, pain management. The osteoarthritis market size is expected to see strong growth in the next few years. It will grow
Global Caps And Closures Market 2024 : Trends, Business Growth And Major Driving Factors | Reynolds Group Holdings Limited, WestRock Company, Ball Corporation
Global Caps And Closures Market 2024 : Trends, Business Growth And Major Driving …
"The caps and closures market size has grown strongly in recent years. It will grow from $73.17 billion in 2023 to $77.46 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to consumer packaging trends, food and beverage industry growth, pharmaceutical packaging needs, environmental concerns. The caps and closures market size is expected to see strong growth

All 5 Releases


More Releases for RSV

RSV Diagnostics Market | Pin-Point Analysis for Changing Competitive Dynamics
Human respiratory syncytial virus (RSV) is a virus that commonly causes lower respiratory tract infection. Human respiratory syncytial virus infections are acquired during hospital visits. Infants and in young children are more prone to human respiratory syncytial virus (RSV) infection. RSV infections affect lungs and respiratory tract of an individual. In premature babies and children with previous presence of diseases, RSV infections affect heart and immune systems as well resulting
Global RSV Diagnostics Market 2018-2025 bio Mérieux, Abbott, Roche, BD
A market study "Global RSV Diagnostics Market" examines the performance of the RSV Diagnostics market 2018. It encloses an in-depth Research of the RSV Diagnostics market state and the competitive landscape globally. This report analyzes the potential of RSV Diagnostics market in the present and the future prospects from various angles in detail. The Global RSV Diagnostics Market 2018 report includes RSV Diagnostics market Revenue, market Share, RSV Diagnostics industry volume,
RSV Diagnostics Market Trend | Industry Analysis Report, 2019
Human respiratory syncytial virus (RSV) is a virus that commonly causes lower respiratory tract infection. Human respiratory syncytial virus infections are acquired during hospital visits. Infants and in young children are more prone to human respiratory syncytial virus (RSV) infection. RSV infections affect lungs and respiratory tract of an individual. In premature babies and children with previous presence of diseases, RSV infections affect heart and immune systems as well resulting
RSV Diagnostics Market Set to Surge Significantly During 2019
Human respiratory syncytial virus (RSV) is a virus that commonly causes lower respiratory tract infection. Human respiratory syncytial virus infections are acquired during hospital visits. Infants and in young children are more prone to human respiratory syncytial virus (RSV) infection. RSV infections affect lungs and respiratory tract of an individual. In premature babies and children with previous presence of diseases, RSV infections affect heart and immune systems as well resulting
Global Pediatric Respiratory Syncytial Virus ( RSV) Prophylactics Sales Market R …
Qyresearchreports include new market research report "Global Pediatric Respiratory Syncytial Virus ( RSV) Prophylactics Sales Market Report 2017" to its huge collection of research reports. This research report gives a definitive review on the Pediatric Respiratory Syncytial Virus ( RSV) Prophylactics as in light of a segmented pattern. Entry variables managed in the report incorporate the distinctive services or products offered by the market players alongside the free market activity scales
OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) - Opportunity Analysis An …
Summary Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense ribonucleic acid (RNA) pneumovirus belonging to the family of Paramyxoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from respiratory disease. RSV can cause upper respiratory tract infections (the common cold) and is the most important cause of lower respiratory tract infections, such